Related Experiment Video
Updated: Jun 22, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[Interferon-alpha as treatment option in severe persistent uncontrolled bronchial asthma: an open label study]
C Kroegel1, N Bergmann, C Heider
1Pneumologie & Allergologie/Immunologie, Klinik für Innere Medizin I, Friedrich-Schiller-Universität, Jena. claus.kroegel@med.uni-jena.de
Pneumologie (Stuttgart, Germany)
|June 12, 2009
Summary
Interferon-alpha (IFN-alpha) treatment significantly improved lung function and reduced medication needs in severe asthma patients. This therapy allowed for a reduction or discontinuation of oral glucocorticoids (GCs), demonstrating sustained clinical benefits.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Severe persistent asthma often requires long-term oral glucocorticoid (GC) therapy.
- Uncontrolled asthma poses significant challenges to patient quality of life and healthcare systems.
Purpose of the Study:
- To evaluate the long-term safety and therapeutic effects of Interferon-alpha (IFN-alpha) in patients with severe persistent uncontrolled asthma.
- To assess the impact of IFN-alpha on oral GC dependency.
Main Methods:
- A study involving 16 patients with severe persistent asthma, diagnosed according to established guidelines.
- Eight patients received IFN-alpha (9 microg) three times weekly for at least 12 months, all previously on oral GCs for over 5 years.
- Clinical assessments included lung function, medication use, emergency visits, hospitalizations, and patient diaries.
Main Results:
- IFN-alpha improved lung function parameters (FEV1, FEV1/IVC, RV, Rtot) and morning peak expiratory flow.
- Significant reductions were observed in reliever medication use, nocturnal awakenings, emergency visits, and hospitalizations.
- Oral GC dosage was tapered, with five patients discontinuing GCs entirely; blood eosinophil counts decreased.
Conclusions:
- IFN-alpha treatment leads to sustained clinical improvement in severe, GC-dependent asthma.
- IFN-alpha facilitates reduction or discontinuation of oral GCs.
- While generally safe, isolated cases of severe side effects like autoimmune thyroiditis were noted.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:30Asthma-IV: Nursing Management
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...